1		Impact of loss-of-function in angiopoietin-like 4 on the human	
2		phenome	
3			
4		Eloi Gagnon, MA <sup>1</sup> , Jérome Bourgault, MSc <sup>1</sup> , Émilie Gobeil MSc <sup>1</sup> ,	
5		Sébastien Thériault, MD, MSc <sup>1,3</sup> and Benoit J. Arsenault, PhD <sup>1,2</sup> *	
6			
7	1)	Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec,	
8		Québec (QC), Canada	
9	2)	Department of Medicine, Faculty of Medicine, Université Laval, Québec (QC), Canada	
10	3)	Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of	
11		Medicine, Université Laval, Québec (QC), Canada	
12			
13			
14	*Ac	Idress for correspondence	
15	Ben	oit Arsenault, PhD	
16	Cen	tre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec —	
17	Université Laval		
18	Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy		
19	Québec (QC), Canada G1V 4G5		
20	Tele	ephone: 418-656-8711 ext. 3498	
21	Ema	ail: <u>benoit.arsenault@criucpq.ulaval.ca</u>	
22			

Gagnon et al.

23	Abstract
24	
25	Background: Carriers of the E40K loss-of-function variant in Angiopoietin-like 4 (ANGPTL4),
26	have lower plasma triglyceride levels as well as lower rates of coronary artery disease (CAD)
27	and type 2 diabetes (T2D). These genetic data suggest ANGPTL4 inhibition as a potential
28	therapeutic target for cardiometabolic diseases. However, it is unknown whether the association
29	between E40K and human diseases is due to linkage disequilibrium confounding. The broader
30	impact of genetic ANGPTL4 inhibition is also unknown, raising uncertainties about the safety
31	and validity of this target.
32	Methods: To assess the impact of ANGPLT4 inhibition, we evaluated the impact of E40K and
33	other loss-of-function variants in ANGPTL4 on a wide range of health markers and diseases The
34	E40K impact was assessed in 29 publicly available genome-wide association meta-analyses of
35	European ancestry on cardiometabolic traits and diseases as well as 1589 diseases assessed in
36	electronic health record within FinnGen (n=309,154). To ensure that these relationships were
37	truly causal, and not driven by other correlated variants, we used the Bayesian fine mapping
38	algorithm CoPheScan.
39	Results: The CoPheScan posterior probability of E40K being the causal variant for triglyceride
40	was 99.99%, validating the E40K to proxy lifelong lower activity of ANGPTL4. The E40K
41	mutation was associated with lower risk of CAD (odds ratio [OR]=0.84, 95% CI=0.81 to 0.87,
42	p=3.6e-21) and T2D (OR=0.91, 95% CI=0.87 to 0.95, p=2.8e-05) in GWAS meta-analyses, with
43	results replicated in FinnGen. These significant results were also replicated using other rarer
44	loss-of-function variants identified through whole exome sequencing in 488,278 participants of
45	various ancestry in the UK Biobank. Using a Mendelian randomization study design, the E40K
46	variant effect on cardiometabolic diseases was concordant with lipoprotein lipase enhancement
47	(r=0.85), but not hepatic lipaseenhancement (r=-0.10), suggesting that ANGPTL4 effects on
48	cardiometabolic diseases are potentially mainly mediated through lipoprotein lipase. The E40K
49	variant did not significantly increase the risk of any of the 1589 diseases tested in FinnGen.
50	Conclusion: ANGPTL4 inhibition may represent a potentially safe and effective target for
51	cardiometabolic diseases prevention or treatment.
52	

*Gagnon et al.* 

3

#### Introduction

# 53

54

55 Angiopoietin-like 4 (ANGPTL4) plays a key role in lipoprotein-lipid metabolism and energy 56 patitioning. ANGPTL4 inhibits lipoprotein lipase (LPL) mediated lipoprotein uptake by adipose 57 tissue leading to a decrease in circulating lipoproteins and lipids (Kersten 2021). Carriers of the 58 E40K loss-of-function variant in ANGPTL4 are characterized by lower plasma triglyceride levels 59 as well as lower rates of coronary heart disease (CAD) and type 2 diabetes (T2D) (Dewey et al. 2016; Gusarova et al. 2018). These genetic data suggest that ANGPTL4 inhibition may become a 60 61 pharmacological strategy of interest in the prevention or treatment of cardiometabolic diseases, especially in individuals with elevated triglycerides levels. For ANGPTL4 to be a viable target, 62 63 its inhibition must be proven safe. Concerns about the safety of ANGPTL4 inhibition arise from 64 the observation that monoclonal antibody-induced ANGPTL4 inhibition in mice and monkeys led to the accumulation of lipid in mesenteric lymph nodes (Dewey et al. 2016). Consequently, 65 66 the safety of ANGPTL4 inhibition in humans remains uncertain. 67 A powerful method to understand the functional impact of proteins such as ANGPTL4 is to 68 69 leverage their loss-of-function variants. Genetic variations are randomly distributed during 70 gametogenesis and remain constant throughout life, making their associations with diseases 71 unlikely to be influenced by environmental confounding factors or reverse causality, hence likely 72 to be causal. The most common functional variant in ANGPTL4 is E40K, which substitutes a glutamic acid for a lysine giving rise to an unstable ANGPTL4 protein (Yin et al. 2009). The 73 74 frequency of E40K carriers varies from 0.1% in individuals of African ancestry, to 75 approximately 3% in individuals of European ancestry to 18% in a Tunisian population (Abid et 76 al. 2016). The well-replicated associations of E40K with lipid levels and diseases could be 77 spurious (i.e., non-causal) if driven by another correlated variant. In fact, the previous cohort 78 studies on E40K carriers were unable to distinguish true causal effects from confounding due to 79 linkage disequilibrium (Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia 80 Investigators et al. 2016; Dewey et al. 2016; Gusarova et al. 2018). To address linkage 81 disequilibrium confounding, it is essential to employ fine mapping methods such as CoPheScan

82 (Coloc adapted Phenome-wide Scan) (Manipur et al. 2023). CoPheScan is a Bayesian approach

Gagnon et al.

40K ding due 3
40K ding due 3
40K ding due 3
ding due
5
based on
able 1).
dson et
et al.
er
,
ks
). For
n and
ed in
tandard
e other
S.
stinct
•
an
nrs) and

Gagnon et al.

5

114 the substantial fraction of hospital-based recruitment, FinnGen is enriched for disease end-points.

All end-points were adjusted for sex, age, genotyping batch and ten first principal genetic

116 components as covariates prior to GWAS. All GWAS were performed using the SAIGE

- 117 (v.0.35.8.8) algorithm (Zhou et al. 2018).
- 118

119 <u>Genetic colocalisation</u>

120 To test for confounding due to linkage disequilibrium, we used the CoPheScan algorithm. 121 CoPheScan is a Bayesian approach that integrates the linkage disequilibrium matrix and 122 information on the neighbouring variants to address linkage disequilibrium confounding. We 123 used CoPheScan to help distinguish the E40K associations with traits that might be confounded 124 by linkage disequilibrium from those that are true effects. We included all SNPs within 300 Kb 125 upstream or downstream of the ANGPTL4 gene region and systematically tested whether the 126 E40K was the likely causal variant for all tested traits. CoPheScan priors were computed using a 127 hierarchical Bayesian model. Bayes factors were calculated using the SuSIE algorithm allowing 128 for multiple causal variants. SuSIE was computed with a LD matrix obtained using the 1000-129 genome reference panel of individuals of European ancestry (Zou et al. 2022). CoPheScan 130 returns posterior probability for three mutually exclusive hypotheses: H<sub>n</sub>=No association with the 131 query trait; H<sub>a</sub>=Causal association of a variant other than the query variant with the query trait; 132 and  $H_c$ =Causal association of the query variant with the query trait. A high  $H_c$  supports that the 133 association is not due to linkage disequilibrium.

134

135 We investigated shared genetic etiology across lipids and cardiometabolic diseases using multi-136 trait colocalization analyses with the HyPrColoc R package (Foley et al., 2021). HyPrColoc 137 extends traditional genetic colocalization methods by estimating posterior probability of more 138 than two traits sharing the same causal variants. If the traits do not share a causal SNP, a branch-139 and-bound selection algorithm is employed to highlight a subset of traits that share a causal SNP. 140 We used the default uniform prior for the analysis. Prior.1 -the prior probability of a SNP being 141 associated with one trait- was set to 1e-4 and prior.c -the probability of a SNP being associated 142 with an additional trait given that the SNP is associated with at least one other trait- was set to 143 0.02. HyPrColocalization analyses are sensitive to the choice of priors. The priors were therefore 144 iteratively incremented to assess the stability of clusters as a sensitivity analysis. All analyses

*Gagnon et al.* 

6

145 were performed with the genetic region spanning 300 Kb around the ANGPTL4 gene region. The 146 colocalization events were visualized with regional stack plot created with the gassocplot

- 147 package.
- 148

#### 149 ANGPTL4 loss-of-function mutations in UK Biobank

150 Access to the UK Biobank was granted under UK Biobank application 25205. The UK Biobank 151 is a population-based cohort of approximately 500,000 participants, aged 40 to 69 years recruited 152 during 2006–2010 from several centres across the UK. We studied a subsample of 488,278 153 individuals from mixed ancestries with whole exome sequence available. These sequences were 154 annotated with the Ensembl Variant Effect Predictor (McLaren et al., 2016) to identify loss-of-155 function variants in the ANGPTL4 gene region. Loss-of-function variants were defined as either 156 frameshift, missense, splice, nonsense, start-lost or stop-lost variants and grouped according to 157 the Phred-scaled Combined Annotation Dependent Depletion (CADD) score (Rentzsch et al., 158 2021). Noncarriers of these variants were assigned to the control group, carriers with at least one 159 variants with CADD score > 20 and significantly associated with triglycerides (p < 0.05) were 160 assigned to the carrier group, individuals with loss-of-function mutation CADD < 20 or not 161 associated with triglycerides were excluded. The E40K variant CADD score was 31 and it was 162 associated with triglyceride levels at p<7e-136. To specifically assess the impact of other loss-of-163 function mutations in ANGPTL4, the analyses were performed by including and excluding E40K 164

165

carriers.

We defined CAD, T2D and aortic stenosis using Hospital Episode Statistics ICD10 and OPCS4 166

167 codes. CAD cases were defined as participants with ICD-10 codes for MI (I21.X, I22.X, I23.X,

168 I24.1, or I25.2), other acute ischemic heart diseases (I24.0, I24.8-9) or chronic ischemic heart

169 disease (I25.0-25.1, I25.5-25.9), OPSC-4 codes for coronary artery bypass grafting (K40.1-40.4,

170 K41.1-41.4, K45.1-45.5), for coronary angioplasty, with or without stenting (K49.1-49.2,

171 K49.8-49.9, K50.2, K75.1-75.4, K75.8-75.9). AS cases were defined as participants with aortic

172 valve stenosis (I35.X). Participants with rheumatic fever (I01-9) prior to AS diagnosis were

173 excluded from the analysis on AS. T2D cases were defined as participants with type 2 diabetes

174 mellitus (E11, E12, E13, E14).

Gagnon et al.

7

176 To assess the association of loss-of-function mutation on the incidence of diseases, we performed 177 Cox regression. All models were adjusted for variables at recruitment including age at 178 recruitment, sex, and the first 10 principal components of ancestry. To model the lifelong effects 179 of carrier status, the follow-up was started at birth and ended at censoring, death or the date of 180 the data release (2021-11-12). Results are presented as estimated hazard ratios (HR) for incident 181 diagnosis, with 95% confidence intervals. 182 183 *Effect of LPL and hepatic lipase (HL) on cardiometabolic traits and diseases* 184 To gain insights into the mechanism linking genetic ANGPTL4 inhibition to diseases, we 185 investigated the effects of LPL and HL, two enzymes inhibited by ANGPTL4, on 186 cardiometabolic traits and diseases. LPL enhancement was proxied using all independent variants (r<sup>2</sup><0.1) 300 Kb downstream and upstream of the LPL gene region significantly (pval 187 <5e-8) associated with triglyceride levels (Graham et al. 2021). Similarly, HL enhancement was 188 proxied using all independent variants ( $r^2 < 0.1$ ) 300 Kb downstream and upstream of the *LIPC* 189 190 gene region significantly (pval<5e-8) associated with triglyceride levels. Harmonization was 191 performed by aligning the effect sizes of different studies on the same effect allele. When a particular SNP was not present in the outcome datasets, we used a proxy SNPs ( $r^2 > 0.8$ ) obtained 192 193 using linkage disequilibrium information from the 1000 Genomes Project European samples. 194 Instrument strength was assessed using the F-statistic (Burgess, Thompson, and CRP CHD Genetics Collaboration 2011), and the variance explained assessed using the  $r^2$  (Pierce, Ahsan, 195 196 and VanderWeele 2011). The effect of each gene on cardiometabolic traits and diseases was 197 calculated using the inverse variance weighted method with multiplicative random effects 198 (Burgess, Foley, and Zuber 2018) when the number of genetic instruments were over one, or the 199 Wald ratio in the case of the E40K because the number of instruments was equal to one. We 200 compared the effect of LPL and HL on cardiometabolic traits and diseases to the ANGPTLA 201 inhibition on these same cardiometabolic traits and diseasesu using a Pearson's correlation 202 coefficient. 203 204 205 **Results** 206

*Gagnon et al.* 

8

207 The E40K variant was associated with a more favorable lipoprotein-lipid profile, including lower 208 triglyceride and apolipoprotrein (apo) B levels, higher HDL cholesterol levels, but was not 209 associated with LDL cholesterol levels (Figure 1). Additionally, it was associated with lower 210 waist-to-hip ratio, but not with BMI, indicating a more favourable body fat distribution in 211 carriers. Information on the GWAS summary statistics used are presented in Supplementary 212 Table 1. Overall, the E40K showed favorable or neutral associations with the 20 213 cardiometabolic traits tested (Supplementary Table 2). 214 215 The E40K variant was protective for several cardiometabolic diseases including aortic stenosis 216 (odds ratio [OR] = 0.82, 95% CI=0.74 to 0.92, p=7.1e-04), CAD (OR = 0.84, 95% CI=0.81 to 217 0.87, p=3.6e-21) and T2D (OR = 0.91, 95% CI=0.87 to 0.95, p=2.8e-05) (Figure 2). The E40K was also associated with lower risk of stroke, ischemic stroke and heart failure. There was no 218 219 evidence for an association with acute pancreatitis, chronic kidney disease, or non-alcoholic fatty 220 liver disease. The E40K was also associated with longer parental lifespan, indicating a 221 potentially favourable benefit/risk balance (Figure 1). In summary, the E40K variant was either

222 protective or neutral of all cardiometabolic diseases tested.

223

224 Other less frequent loss-of-function mutations in ANGPTL4 were also associated with healthier 225 lipid levels and decreased risk of diseases (Figure 3). By scanning whole-exome sequence of UK 226 biobank participants, we identified 2835 carriers (excluding E40K) or 20,015 carriers (including 227 E40K) of deleterious ANGPTL4 variants (CADD score > 20 and associated with triglycerides 228 with a p-value<0.05). ANGPTL4 loss-of-function carriers had lower levels of triglycerides, 229 higher levels of HDL cholesterol and lower incidence of T2D (Figure 3). When including E40K 230 carriers, loss-of-function in ANGPTL4 was associated with lower CAD incidence (Figure 3 231 panel B). When excluding E40K carriers, loss-of-function in ANGPTL4 was associated with 232 lower CAD incidence but the association did not reach statistical significance (HR = 0.9095%233 CI=0.80 to 1.02, p=9.9e-02). Loss-of-function in ANGPTL4 was associated with lower aortic 234 stenosis incidence only when including E40K carriers. The directionally consistent associations 235 of E40K and other rarer loss-of-function variant in ANGPTL4 support the role of ANGPTL4 in 236 CAD and T2D.

Gagnon et al.

9

238 The E40K protective effects on diseases were not due to confounding by linkage disequilibrium 239 as demonstrated by colocalization algorithms. Within the ANGPTL4 gene region +/- 300 Kb, 240 CoPheScan and HyPrColoc prioritised E40K as the unique causal variant. For example, although 241 the CoPhesScan posterior probability of E40K being the unique causal variant was 0.06% for 242 AS, this probability was 98% for T2D and 99.99% for triglyceride levels, HDL cholesterol 243 levels, and CAD (Supplementary Table 3). These high probabilities support that E40K 244 associations are causal and unaffected by linkage disequilibrium confounding. Similarly, the 245 HyPrColoc algorithm showed a posterior probability of multi-trait colocalization of 0.79 for 246 HDL cholesterol levels, triglyceride levels, T2D, CAD and AS (Figure 4). Notably, the 247 rs116843064-A (i.e., the E40K) explained 100% of the posterior probability of multi-trait 248 colocalization, providing evidence for E40K as a shared causal variant. In summary, both 249 colocalization approaches consistently validated E40K as a reliable genetic proxy for lifelong

- 250 ANGPTL4 inhibition.
- 251

#### 252 <u>Phenome-wide study of ANGPTL4 E40K in FinnGen</u>

To assess the safety of ANGPTL4 inhibition, we examined the impact of E40K on 1589 diseases in FinnGen. E40K was associated with a lower risk of aortic stenosis, CAD and T2D, replicating our initial results obtained through GWAS meta-analysis (Figure 5). The E40K variant was not associated with lymphadenopathy, ascites, or peritonitis, as observed in whole-body *ANGPTL4* knockout mice. Notably, the E40K did not significantly increase the risk of any of the other diseases tested suggesting that the benefits of genetic inhibition of *ANGPTL4* may have more health advantages than consequences (Supplementary Table 2).

260

#### 261 *Exploring E40K mechanisms*

262 The impact of ANGPTL4 on diseases is likely tied to its inhibition of enzymes such as LPL

andHL. To shed light on this mechanism, we assessed the effect of LPL and HL on

264 cardiometabolic traits and diseases and compared their effects with those resulting from

ANGPTL4 inhibition (Supplementary Table 4). LPL and HL enhancement were proxied with

266 independent SNPs in their respective gene region +/- 300 Kb significantly associated (pval<5e-8)

267 with triglycerides. Specifically LPL enhancement was proxied with 71 independent SNPs in the

268 LPL region +/- 300 Kb significantly associated with triglycerides ( $r^2 = 1.92\%$ ; F-statistics = 343)

Gagnon et al.

269	and HL enhancement was proxied with 23 SNPs in the region of the gene encoding HL
270	significantly associated with triglyceride levels ( $r^2 = 0.24\%$ ; F-statistics = 131). Genetically
271	predicted enhancement of LPL and ANGPTL4 inhibition had similar effects on cardiometabolic
272	traits and diseases (Pearson's correlation = $0.85$ ) (Figure 6). By contrast, ANGPTL4 and HL had
273	distinct associations with cardiometabolic traits and diseases (Pearson's correlation = $-0.10$ ).
274	These data suggest that ANGPTL4 effects on cardiometabolic traits and diseases are potentially
275	mainly mediated through its effect on LPL, but not through its effect on HL.
276	
277	Discussion
278	
279	To explore the effects of genetic inhibition of ANGPTL4 on human health, we performed a
280	systematic assessment of loss-of-function in ANGPTL4 and their associations with
281	cardiometabolic traits and human diseases. The E40K, the most common loss-of function variant
282	in ANGPTL4, was protective for CAD and T2D, as suggested by previous reports, as well as
283	protective for aortic stenosis,. These associations were not confounded by linkage
284	disequilibrium, consistent with a true causal effect of ANGPTL4 genetic inhibition. Importantly,
285	the E40K was not significantly associated with an increase in any of the 1589 diseases tested.
286	Altogether, these results provide robust genetic evidence that ANGPTL4 may represent a safe
287	and effective therapeutic target to prevent or treat cardiometabolic diseases.
288	
289	Our phenome-wide association study showed that the E40K variant lowered risk of T2D, CAD
290	and AS, but did not increase the risk of any of the 1589 tested, supporting ANGPTL4 inhibition
291	as a viable therapy. Both E40K and other rarer loss-of-function mutations in ANGPTL4 were
292	associated with lower triglyceride levels and higher HDL cholesterol levels. Similar
293	perturbations of lipid levels have been observed in mice with ANGPTL4 whole-body knockout
294	(Lichtenstein et al. 2010), liver-specific knockout (Singh et al. 2021) and adipose tissue-specific
295	knockout (Aryal et al. 2018), providing external validation for our use of the E40K to proxy
296	ANGPTL4 inhibition. The inhibition of ANGPTL4 seemed to be associated with
297	lymphadenopathy, ascites, and peritonitis in mice (Lichtenstein et al. 2010) and monkeys
298	(Dewey et al. 2016). By contrast, the ANGPTL4 E40K variant did not significantly increase the
299	risk of these diseases, supporting the safety of ANGPTL4 inhibition in humans. The safety of

Gagnon et al.

11

human ANGPTL4 inhibition is further supported by a recent randomized, double-blind, placebocontrolled Phase I study evaluating the safety of a GalNAc conjugated ASO against ANGPTL4.
The treatment did not cause serious adverse events but caused mild resolving injection site
reactions (89% of treated, 0% of placebo) (K. Nilsson 2023).

304

305 Our results show that genetically predicted inhibition of ANGPTL4 and genetically predicted 306 enhancement of LPL have very similar effects on cardiometabolic diseases (r=0.85), suggesting 307 that the effects of ANGPTL4 on cardiometabolic diseases are potentially mainly mediated 308 through LPL. In support of this notion, ANGPTL4 was shown to bind and inhibit LPL (Gutgsell 309 et al. 2019). Furthermore, the E40K proxying inhibition of ANGPTL4 and rs115849089 A 310 proxying enhancement of the activity of LPL were shown to have very similar effects on 311 metabolites (r2>0.96), strongly suggesting that ANGPTL4 impacts plasma lipids exclusively via 312 LPL (Wang, n.d.; Landfors, Chorell, and Kersten 2023). ANGPTL4 could also antagonise HL, as 313 mice with hepatocyte-specific knock of ANGPTL4 have higher HL activity (Singh et al. 2021). 314 Despite the potential inhibitory effect of ANGPTI4 on HL, we did not find evidence that 315 ANGPTL4 influenced cardiometabolic disease through HL. In summary, our results and those of 316 others (Landfors, Chorell, and Kersten 2023) support that ANGPTL4 effects on diseases are

317 related to the activity of *LPL* and not *LIPC*, the gene encoding HL.

318

319 Our genetic data shows that loss-of-function variants in ANGPTL4 have no effect on 320 lipoprotein(a), no effect on LDL cholesterol, a weak effect on ApoB and a stronger effect on 321 CAD. These genetic data suggest that ANGPTL4 inhibition protects from CAD in part from 322 ApoB lowering, but also through other mechanisms. The major effect of ANGPTL4 inhibition is 323 triglyceride lowering, which has been initially argued as an independent causal factor for CAD 324 (Gotto 1998). However, this notion has recently been challenged by high throughput 325 multivariable Mendelian randomization studies showing no effect of triglyceride when ApoB is 326 taken into account (Zuber et al. 2021). Genetic data support that the clinical benefit of lowering 327 TG and LDL-C levels is proportional to the absolute change in ApoB (Ference et al. 2019), 328 further emphasizing ApoB as the main risk factor. Hence, genetic inhibition of ANGPTL4 seems 329 to reduce CAD risk not only through its lowering of ApoB-containing particle, but also possibly 330 though other mechanism. For example, our data and those of others (Aryal et al. 2018) show that

Gagnon et al.

331	ANGPTL4 inhibition promotes fat storage at the periphery instead of at the abdomen, which
332	protects from atherosclerotic diseases (Després 2012). ANGPLT4 inhibition could also improve
333	insulin sensitivity, which could reduce coronary artery disease risk. Altogether, this data shows
334	that ANGPTL4 inhibition may protect from CAD probably through multiple mechanisms,
335	including ApoB lowering, insulin sensitivity and a more favourable body fat distribution.
336	
337	The integration of these results supports that the inhibition of ANGPTL4 activates LPL which
338	ultimately lowers CAD risk through mechanisms that are partly independent of ApoB lowering.
339	Yet, the specific tissue of action remains uncertain as ANGPTL4 loss-of-function mutations
340	inhibit ANGPTL4 in all tissues. ANGPTL4 is abundantly expressed in numerous human tissues,
341	including kidney, intestine, and heart, but most abundantly in adipose tissue and next in liver
342	(THE GTEX CONSORTIUM 2020). By contrast, LPL and HL are more tissue specific. LPL is
343	expressed 1621 times more in the adipose tissue compared to the liver, whereas the LIPC is
344	expressed 148 times more in the liver compared to the adipose tissue (THE GTEX
345	CONSORTIUM 2020). We have shown that ANGPTL4 effects on diseases may be related to
346	adipose tissue-enriched LPL and not to the liver-enriched LIPC. Therefore, it seems likely that
347	ANGPTL4 acts on diseases primarily through its action in the adipose tissue. Ultimately,
348	whether liver-specific inhibition of ANGPTL4 can increase LPL activity will be settled by future
349	phase 2 trial studying liver targeted ASO on ANGPTL4 (Lipigon Pharmaceuticals 2023).
350	
351	In conclusion, these results support that inhibition of ANGPTL4 may have considerable health
352	benefits such as a reduction in the risk of CAD, T2D and aortic stenosis while possibly
353	increasing lifespan. These effects may be mostly due to the activation of LPL. ANGPTL4
354	inhibition may represent a potentially safe and effective target for cardiometabolic diseases
355	prevention or treatment.
356	
357	
358	Declarations
359	
360	Institutional Review Board Approval

Gagnon et al.

- 361 All data used in this study are in the public domain. All participants provided informed consent
- 362 and study protocols were approved by their respective local ethical committees. This project was
- approved by the Institutional Review Board of the Quebec Heart and Lung Institute.
- 364 *Data Availability*
- 365 All data used in this study are in the public domain. Supplementary Table 1 describes the data
- 366 used and relevant information to retrieve the summary statistics.
- 367 <u>Code Availability</u>
- 368 Code to reproduce the results of this manuscript is available on
- 369 https://github.com/gagelo01/ANGPTL4
- 370 *Competing interests*
- 371 BJA is a consultant for Novartis, Eli Lilly, Editas Medicine and Silence Therapeutics and has
- 372 received research contracts from Pfizer, Eli Lilly and Silence Therapeutics.
- 373 <u>Funding</u>
- 374 EG holds a doctoral research award from the Fonds de recherche du Québec: Santé. (FRQS). JB
- holds a masters research award from the FRQS. ÉG holds a Doctoral Research Award from the
- 376 Canadian Institutes of Health Research. BJA holds a senior scholar awards from the FRQS.
- 377 Authors' contributions
- 378 Data acquisition and analysis EG, JB, ÉG and ST. Conception and design EG, BJA. Drafting of
- the work EG, BJA. All authors approved the final version of the manuscript.
- 380
- 381
- 382
- 383
- 384

### References

- Abid, Kaouthar, Thouraya Trimeche, Donia Mili, Mohamed Amine Msolli, Imen Trabelsi, Semir
  Nouira, and Abderraouf Kenani. 2016. 'ANGPTL4 Variants E40K and T266M Are
  Associated with Lower Fasting Triglyceride Levels and Predicts Cardiovascular Disease
  Risk in Type 2 Diabetic Tunisian Population'. *Lipids in Health and Disease* 15 (March):
  63. https://doi.org/10.1186/s12944-016-0231-6.
  Aragam, Krishna G., Tao Jiang, Anuj Goel, Stavroula Kanoni, Brooke N. Wolford, Deepak S.
  - Atri, Elle M. Weeks, et al. 2022. 'Discovery and Systematic Characterization of Risk
     Variants and Genes for Coronary Artery Disease in over a Million Participants'. *Nature*
  - *Genetics* 54 (12): 1803–15. https://doi.org/10.1038/s41588-022-01233-6.

Gagnon et al.

394	Aryal, Binod, Abhishek K. Singh, Xinbo Zhang, Luis Varela, Noemi Rotllan, Leigh Goedeke,
395	Balkrishna Chaube, et al. 2018. 'Absence of ANGPTL4 in Adipose Tissue Improves
396	Glucose Tolerance and Attenuates Atherogenesis'. JCI Insight 3 (6): e97918.
397	https://doi.org/10.1172/jci.insight.97918.
398	Burgess, Stephen, Christopher N. Foley, and Verena Zuber. 2018. 'Inferring Causal
399	Relationships Between Risk Factors and Outcomes from Genome-Wide Association
400	Study Data'. Annual Review of Genomics and Human Genetics 19 (August): 303–27.
401	https://doi.org/10.1146/annurev-genom-083117-021731.
402	Burgess, Stephen, Simon G Thompson, and CRP CHD Genetics Collaboration. 2011. 'Avoiding
403	Bias from Weak Instruments in Mendelian Randomization Studies'. International
404	Journal of Epidemiology 40 (3): 755–64. https://doi.org/10.1093/ije/dvr036.
405	Després, Jean-Pierre. 2012. 'Body Fat Distribution and Risk of Cardiovascular Disease'.
406	<i>Circulation</i> 126 (10): 1301–13.
407	https://doi.org/10.1161/CIRCULATIONAHA.111.067264.
408	Dewey, Frederick E., Viktoria Gusarova, Colm O'Dushlaine, Omri Gottesman, Jesus Treios,
409	Charleen Hunt, Cristopher V. Van Hout, et al. 2016, 'Inactivating Variants in ANGPTL4
410	and Risk of Coronary Artery Disease'. New England Journal of Medicine 374 (12):
411	1123–33. https://doi.org/10.1056/NEJMoa1510926.
412	Ference, Brian A., John J. P. Kastelein, Kausik K. Ray, Henry N. Ginsberg, M. John Chapman,
413	Chris J. Packard, Ulrich Laufs, et al. 2019. 'Association of Triglyceride-Lowering LPL
414	Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease'.
415	JAMA 321 (4): 364–73. https://doi.org/10.1001/jama.2018.20045.
416	Ghodsian, Nooshin, Erik Abner, Connor A. Emdin, Émilie Gobeil, Nele Taba, Mary E. Haas,
417	Nicolas Perrot, et al. 2021. 'Electronic Health Record-Based Genome-Wide Meta-
418	Analysis Provides Insights on the Genetic Architecture of Non-Alcoholic Fatty Liver
419	Disease'. Cell Reports. Medicine 2 (11): 100437.
420	https://doi.org/10.1016/j.xcrm.2021.100437.
421	Gotto, A. M. 1998. 'Triglyceride as a Risk Factor for Coronary Artery Disease'. The American
422	Journal of Cardiology 82 (9A): 22Q-25Q. https://doi.org/10.1016/s0002-9149(98)00770-
423	X.
424	Graham, Sarah E., Shoa L. Clarke, Kuan-Han H. Wu, Stavroula Kanoni, Greg J. M. Zajac,
425	Shweta Ramdas, Ida Surakka, et al. 2021. 'The Power of Genetic Diversity in Genome-
426	Wide Association Studies of Lipids'. Nature 600 (7890): 675–79.
427	https://doi.org/10.1038/s41586-021-04064-3.
428	Gusarova, Viktoria, Colm O'Dushlaine, Tanya M. Teslovich, Peter N. Benotti, Tooraj Mirshahi,
429	Omri Gottesman, Cristopher V. Van Hout, et al. 2018. 'Genetic Inactivation of
430	ANGPTL4 Improves Glucose Homeostasis and Is Associated with Reduced Risk of
431	Diabetes'. Nature Communications 9 (1): 2252. https://doi.org/10.1038/s41467-018-
432	04611-z.
433	Gutgsell, Aspen R., Swapnil V. Ghodge, Albert A. Bowers, and Saskia B. Neher. 2019.
434	'Mapping the Sites of the Lipoprotein Lipase (LPL)-Angiopoietin-like Protein 4
435	(ANGPTL4) Interaction Provides Mechanistic Insight into LPL Inhibition'. The Journal
436	of Biological Chemistry 294 (8): 2678–89. https://doi.org/10.1074/jbc.RA118.005932.
437	K. Nilsson, Stefan. 2023. 'First-in-Human Phase I Trial with Lipigons Lipid-Lowering
438	Candidate Lipisense - Lipigon'. 12 July 2023.

Gagnon et al.

439	https://www.lipigon.se/media/pressmeddelanden/first-in-human-phase-i-trial-with-
440	lipigons-lipid-lowering-ca-96244.
441	Kersten, Sander. 2021. 'Role and Mechanism of the Action of Angiopoietin-like Protein
442	ANGPTL4 in Plasma Lipid Metabolism'. Journal of Lipid Research 62 (January).
443	https://doi.org/10.1016/j.jlr.2021.100150.
444	Kurki, Mitja I., Juha Karjalainen, Priit Palta, Timo P. Sipilä, Kati Kristiansson, Kati M. Donner,
445	Mary P. Reeve, et al. 2023. 'FinnGen Provides Genetic Insights from a Well-Phenotyped
446	Isolated Population'. Nature 613 (7944): 508-18. https://doi.org/10.1038/s41586-022-
447	05473-8.
448	Landfors, Fredrik, Elin Chorell, and Sander Kersten. 2023. 'Genetic Mimicry Analysis Reveals
449	the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4'.
450	Journal of Lipid Research 64 (1): 100313. https://doi.org/10.1016/j.jlr.2022.100313.
451	Lichtenstein, Laeticia, Frits Mattijssen, Nicole J. de Wit, Anastasia Georgiadi, Guido J.
452	Hooiveld, Roelof van der Meer, Yin He, et al. 2010. 'Angptl4 Protects against Severe
453	Proinflammatory Effects of Saturated Fat by Inhibiting Fatty Acid Uptake into
454	Mesenteric Lymph Node Macrophages'. Cell Metabolism 12 (6): 580–92.
455	https://doi.org/10.1016/j.cmet.2010.11.002.
456	Lipigon Pharmaceuticals, AB. 2023. 'Lipisense® Progressing to Phase II - What Comes Next?'
457	12 December 2023.
458	https://view.news.eu.nasdaq.com/view?id=b012022862ab3ead192d18508d5d82374&lan
459	g=en&src=micro.
460	Liu, Yi, Nicolas Basty, Brandon Whitcher, Jimmy D. Bell, Elena P. Sorokin, Nick van Bruggen,
461	E. Louise Thomas, and Madeleine Cule. 2021. 'Genetic Architecture of 11 Organ Traits
462	Derived from Abdominal MRI Using Deep Learning'. <i>eLife</i> 10 (June): e65554.
463	https://doi.org/10.7554/eLife.65554.
464	Mahajan, Anubha, Cassandra N. Spracklen, Weihua Zhang, Maggie C. Y. Ng, Lauren E. Petty,
465	Hidetoshi Kitajima, Grace Z. Yu, et al. 2022. 'Multi-Ancestry Genetic Study of Type 2
466	Diabetes Highlights the Power of Diverse Populations for Discovery and Translation'.
467	Nature Genetics 54 (5): 560–72. https://doi.org/10.1038/s41588-022-01058-3.
468	Manipur, Ichcha, Guillermo Reales, Jae Hoon Sul, Myung Kyun Shin, Simonne Longerich,
469	Adrian Cortes, and Chris Wallace. 2023. 'CoPheScan: Phenome-Wide Association
470	Studies Accounting for Linkage Disequilibrium'. Preprint. Genetics.
471	https://doi.org/10.1101/2023.06.29.546856.
472	Mishra, Aniket, Rainer Malik, Tsuyoshi Hachiya, Tuuli Jürgenson, Shinichi Namba, Daniel C.
473	Posner, Frederick K. Kamanu, et al. 2022, 'Stroke Genetics Informs Drug Discovery and
474	Risk Prediction across Ancestries'. <i>Nature</i> 611 (7934): 115–23.
475	https://doi.org/10.1038/s41586-022-05165-3.
476	Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Nathan O.
477	Stitziel, Kathleen E. Stirrups, Nicholas G. D. Masca, Jeanette Erdmann, Paola G.
478	Ferrario Inke R. König et al. 2016. 'Coding Variation in ANGPTI 4 LPL and SVEP1
479	and the Risk of Coronary Disease' The New England Journal of Medicine 374 (12):
480	1134–44 https://doi.org/10.1056/NEIMoa1507652
481	Pierce, Brandon L. Habibul Ahsan, and Tyler J VanderWeele, 2011 'Power and Instrument
482	Strength Requirements for Mendelian Randomization Studies Using Multiple Genetic
483	Variants' International Journal of Enidemiology 40 (3): 740–52
484	https://doi.org/10.1093/ije/dva151
TUT	μιρυ.// αυτοιχ/ τυ τυ / υ/ αγμιστ.

Gagnon et al.

485	Richardson, Tom G., Eleanor Sanderson, Tom M. Palmer, Mika Ala-Korpela, Brian A. Ference,
486	George Davey Smith, and Michael V. Holmes. 2020. 'Evaluating the Relationship
487	between Circulating Lipoprotein Lipids and Apolipoproteins with Risk of Coronary Heart
488	Disease: A Multivariable Mendelian Randomisation Analysis'. <i>PLoS Medicine</i> 17 (3):
489	e1003062. https://doi.org/10.1371/journal.pmed.1003062.
490	Singh, Abhishek K., Balkrishna Chaube, Xinbo Zhang, Jonathan Sun, Kathryn M. Citrin, Alberto
491	Canfrán-Duque, Binod Arval, et al. 2021, 'Hepatocyte-Specific Suppression of
492	ANGPTL4 Improves Obesity-Associated Diabetes and Mitigates Atherosclerosis in
493	Mice'. Journal of Clinical Investigation 131 (17): e140989.
494	https://doi.org/10.1172/JCI140989.
495	Sinnott-Armstrong, Nasa, Isabel S. Sousa, Samantha Laber, Elizabeth Rendina-Ruedy, Simon E.
496	Nitter Dankel, Teresa Ferreira, Gunnar Mellgren, et al. 2021. 'A Regulatory Variant at
497	3q21.1 Confers an Increased Pleiotropic Risk for Hyperglycemia and Altered Bone
498	Mineral Density'. Cell Metabolism 33 (3): 615-628.e13.
499	https://doi.org/10.1016/j.cmet.2021.01.001.
500	Stanzick, Kira J., Yong Li, Pascal Schlosser, Mathias Gorski, Matthias Wuttke, Laurent F.
501	Thomas, Humaira Rasheed, et al. 2021. 'Discovery and Prioritization of Variants and
502	Genes for Kidney Function in >1.2 Million Individuals'. Nature Communications 12 (1):
503	4350. https://doi.org/10.1038/s41467-021-24491-0.
504	Sveinbjornsson, Gardar, Magnus O. Ulfarsson, Rosa B. Thorolfsdottir, Benedikt A. Jonsson,
505	Eythor Einarsson, Gylfi Gunnlaugsson, Solvi Rognvaldsson, et al. 2022. 'Multiomics
506	Study of Nonalcoholic Fatty Liver Disease'. Nature Genetics 54 (11): 1652-63.
507	https://doi.org/10.1038/s41588-022-01199-5.
508	THE GTEX CONSORTIUM. 2020. 'The GTEx Consortium Atlas of Genetic Regulatory Effects
509	across Human Tissues'. Science 369 (6509): 1318–30.
510	https://doi.org/10.1126/science.aaz1776.
511	Wallace, Chris. 2021. 'A More Accurate Method for Colocalisation Analysis Allowing for
512	Multiple Causal Variants'. PLoS Genetics 17 (9): e1009440.
513	https://doi.org/10.1371/journal.pgen.1009440.
514	Ward, Lucas D., Ho-Chou Tu, Chelsea B. Quenneville, Shira Tsour, Alexander O. Flynn-Carroll,
515	Margaret M. Parker, Aimee M. Deaton, et al. 2021. 'GWAS of Serum ALT and AST
516	Reveals an Association of SLC30A10 Thr95Ile with Hypermanganesemia Symptoms'.
517	Nature Communications 12 (1): 4571. https://doi.org/10.1038/s41467-021-24563-1.
518	Yin, Wu, Stefano Romeo, Shurong Chang, Nick V. Grishin, Helen H. Hobbs, and Jonathan C.
519	Cohen. 2009. 'Genetic Variation in ANGPTL4 Provides Insights into Protein Processing
520	and Function*'. Journal of Biological Chemistry 284 (19): 13213–22.
521	https://doi.org/10.1074/jbc.M900553200.
522	Zhou, Wei, Jonas B. Nielsen, Lars G. Fritsche, Rounak Dey, Maiken E. Gabrielsen, Brooke N.
523	Wolford, Jonathon LeFaive, et al. 2018. 'Efficiently Controlling for Case-Control
524	Imbalance and Sample Relatedness in Large-Scale Genetic Association Studies'. Nature
525	<i>Genetics</i> 50 (9): 1335–41. https://doi.org/10.1038/s41588-018-0184-y.
526	Zou, Yuxin, Peter Carbonetto, Gao Wang, and Matthew Stephens. 2022. 'Fine-Mapping from
527	Summary Data with the "Sum of Single Effects" Model'. <i>PLOS Genetics</i> 18 (7):
528	e1010299. https://doi.org/10.1371/journal.pgen.1010299.
529	Zuber, Verena, Dipender Gill, Mika Ala-Korpela, Claudia Langenberg, Adam Butterworth,
530	Leonardo Bottolo, and Stephen Burgess. 2021. 'High-Throughput Multivariable

Gagnon et al.

- 531 Mendelian Randomization Analysis Prioritizes Apolipoprotein B as Key Lipid Risk
- 532 Factor for Coronary Artery Disease'. International Journal of Epidemiology 50 (3): 893–
- 533 901. https://doi.org/10.1093/ije/dyaa216.
- 534

18

*Gagnon et al.* 

#### **Figure Legends**

**Figure 1. Impact of the** *ANGPTL4* **loss-of function variant E40K on cardiometabolic traits.** All cardiometabolic traits have a SD of one. ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, HDL = high-density lipoprotein, LDL = low-density lipoprotein, WHRadjBMI = waist-to-hip ratio adjusted for body mass index. CI = confidence interval

**Figure 2. Impact of the** *ANGPTL4* **loss-of function variant E40K on cardiometabolic diseases.** NAFLD = non-alcoholic fatty liver disease. CI = confidence interval and OR = Odds ratio.

**Figure 3. Health impact of** *ANGPTL4* **loss-of function mutations in the UK Biobank.** Impact of *ANGPTL4* variants (including E40K and excluding E40K) on A) incidence of coronary artery disease, type 2 diabetes and aortic stenosis and B) high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride levels.

**Figure 4. Multi-trait genetic colocalization for lipids and cardiometabolic diseases.** The left panel shows the regional association plot with the highlighted genetic variant prioritized by HyPrColoc. The right panel shows the heatmap of the proportion of colocalization on different range of prior values.

**Figure 5.** Phenome-wide association study of the *ANGPTL4* loss-of function variant E40K on 1589 diseases in FinnGen. The green line is the threshold for multiple testing significance. Triangles pointing down represent negative associations (i.e., E40K lowers the risk of the disease), whereas triangles pointing up represent positive associations (i.e., E40K increases the risk of the disease). Associations that pass multiple testing correction are annotated and encompass atherosclerotic conditions and type 2 diabetes. Among the triangles pointing up, all are below the green significance line, meaning that E40K is not significantly associated with an increase risk of diseases.

Gagnon et al.

**Figure 6. Impact on genetic inhibition of** *ANGPTL4* **on cardiometabolic traits and diseases in relation with the effect on genetic enhancement of lipoprotein lipase and hepatic lipase on the same traits and diseases.** ANGPTL4 inhibition was proxied with the E40K. Lipoprotein lipase (LPL) and hepatic lipase (HL) enhancing were proxied with variants from their respective gene region significantly associated with triglyceride levels. Each effect is scaled to a one standard deviation effect on triglyceride levels. Panel A) ANGPTL4 inhibition vs. LPL enhancement. Panel B) ANGPTL4 inhibition vs. HL enhancement.

Outcomes	ANGPTL4 E40K	beta (95% CI)	pval
Anthropometric			
Body mass index	i <mark>i⊯</mark> i	0.00 (-0.01 to 0.02)	5.2e-01
WHRadjBMI	H <b>e</b> t	-0.04 (-0.05 to -0.02)	3.9e-07
Glucose homeostasis			
Glucose	H	-0.01 (-0.02 to 0.01)	4.5e-01
Glycated haemoglobin	⊦≡┤	-0.02 (-0.04 to -0.00)	3.7e-02
Insulin resistance	⊢╼→┆	-0.06 (-0.10 to -0.01)	9.4e-03
Insulin sensitivity	è-∎-i	0.05 (0.00 to 0.09)	3.8e-02
Kidney			
Glomerular filtration rate		0.01 (0.00 to 0.02)	3.7e-02
Lifespan			
Parental lifespan	⊦⊷⊣	0.04 (0.02 to 0.06)	1.2e-04
Lipids			
Apolipoprotein B	⊦ <b>≡</b> -	-0.02 (-0.04 to -0.01)	3.0e-03
HDL cholesterol		0.21 (0.21 to 0.22)	1.0e-200
LDL cholesterol	i=1	0.01 (-0.00 to 0.02)	1.7e-01
Lipoprotein (a)	H <mark>a</mark> ⊣	0.01 (-0.01 to 0.03)	4.6e-01
Triglyceride		-0.24 (-0.25 to -0.23)	1.0e-200
Liver			
ALT	ŀ <del>ĸ</del> į	-0.01 (-0.03 to 0.00)	1.6e-01
AST		-0.01 (-0.03 to 0.01)	2.0e-01
Liver Fat	⊢╞┳──┤	0.01 (-0.04 to 0.06)	7.5e-01
Pancreas			
Pancreas Fat	k <mark>i ∎</mark> −1	0.05 (-0.01 to 0.11)	8.9e-02
Vascular			
Diastolic blood pressure	H <b>a</b> i	-0.02 (-0.03 to -0.00)	1.6e-02
Systolic blood pressure	;  =	-0.02 (-0.03 to -0.01)	1.2e-03
	-0.2 -0.1 0 0.1 0.2 Standard deviation (95% CI)		

Outcomes	ANGPTL4 E40K	OR (95% CI)	pval
Glucose homeostasis			
Type 2 diabetes	┝╼┥	0.91 (0.87 to 0.95)	2.8e-05
Kidney			
Chronic Kidney disease	<u>}</u>	1.00 (0.93 to 1.07)	9.5e-01
Lifespan			
Longevity	l <mark>∶</mark> ∎	1.15 (0.98 to 1.36)	8.5e-02
Liver			
NAFLD	<b>⊢</b>	1.01 (0.94 to 1.09)	8.0e-01
Pancreas			
Acute pancreatitis	⊢ <b>∎</b> ¦	0.98 (0.90 to 1.07)	6.9e-01
Vascular			
Aortic stenosis		0.82 (0.74 to 0.92)	7.1e-04
Coronary artery disease	┝╋┥	0.84 (0.81 to 0.87)	3.6e-21
Heart failure	⊢ <b>∎</b> −┤	0.93 (0.88 to 0.99)	1.7e-02
lschemic stroke	┝─■─┤	0.92 (0.87 to 0.98)	1.4e-02
Stroke	0.8 0.9 1 1.1 1.2 1.3 Odds ratio (95% CI)	0.94 (0.89 to 1.00)	4.4e-02

Figure 2.

## A)

Outcomes	Prevalence in carriers	Prevalence in noncarriers	ANGPTL4 loss-of-function mutation carriers	HR (95% CI)	pval
Excluding E40K carriers					
Aortic stenosis	22/2812 (0.8%)	3651/461014 (0.8%)	⊢	H 0.98 (0.65 to 1.49)	9.3e-01
Coronary artery disease	262/2835 (9.2%)	47475/465083 (10.2%)	⊢ <b>=</b> ↓	0.90 (0.80 to 1.02)	9.9e-02
Type 2 diabetes	46/2835 (1.6%)	12091/465083 (2.6%)	<b>⊢</b>	0.67 (0.50 to 0.89)	6.5e-03
Including E40K carriers					
Aortic stenosis	131/19860 (0.7%)	3651/461014 (0.8%)	⊢	0.81 (0.68 to 0.96)	1.7e-02
Coronary artery disease	1842/20015 (9.2%)	47475/465083 (10.2%)	⊦∎⊣	0.89 (0.85 to 0.93)	4.6e-07
Type 2 diabetes	391/20015 (2%)	12091/465083 (2.6%)	⊢	0.79 (0.72 to 0.88)	7.2e-06
			0.7 0.8 1 1.2	_	

B)

Outcomes	ANGPTL4 loss-of-function mutations carriers	Beta (95% CI)	pval
Excluding E40K carriers			
HDL cholesterol	╎┼╼╌┤	0.09 (0.06 to 0.13)	4.9e-07
LDL cholesterol	<b> </b> ■	0.01 (-0.03 to 0.04)	7.1e-01
Triglycerides	<b>⊢</b> ∎→1	-0.12 (-0.16 to -0.09)	6.4e-11
Including E40K carriers			
HDL cholesterol	H	▪ 0.19 (0.17 to 0.20)	4.5e-157
LDL cholesterol	I <del>.∳I</del>	0.00 (-0.01 to 0.01)	9.7e-01
Triglycerides	┝═┤	-0.19 (-0.21 to -0.18)	9.8e-158
-	0.2 -0.1 0 0.1 ( 1-SD deviation scale	0.2	



Figure 4.





Figure 6.